Cargando…

Associations between race and survival in pediatric patients with diffuse large B‐cell lymphoma

BACKGROUND: The purpose of this study was to examine the factors associated with disparities in overall survival (OS) by race in pediatric diffuse large B‐cell lymphoma (DLBCL) patients. METHODS: We evaluated clinical features and survival among patients ≤21 years of age diagnosed with stage I–IV DL...

Descripción completa

Detalles Bibliográficos
Autores principales:	Khullar, Karishma, Plascak, Jesse J., Drachtman, Richard, Cole, Peter D., Parikh, Rahul R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7926019/ https://www.ncbi.nlm.nih.gov/pubmed/33503323 http://dx.doi.org/10.1002/cam4.3736

Ejemplares similares

Outcomes and patterns of care in a nationwide cohort of pediatric medulloblastoma: Factors affecting proton therapy utilization
por: Kopecky, Andrew S., et al.
Publicado: (2017)

The effectiveness of rituximab and HIV on the survival of Ontario patients with diffuse large B‐cell lymphoma
por: Habbous, Steven, et al.
Publicado: (2020)

Interim PET/CT based on visual and semiquantitative analysis predicts survival in patients with diffuse large B‐cell lymphoma
por: Li, Xiaoqian, et al.
Publicado: (2019)

Recent survival trends in diffuse large B‐cell lymphoma––Have we made any progress beyond rituximab?
por: Epperla, Narendranath, et al.
Publicado: (2020)

The impact of structural factors on diagnostic delay in diffuse large B‐cell lymphoma
por: Zurko, Joanna C., et al.
Publicado: (2019)

Microsatellite instability and its associations with the clinicopathologic characteristics of diffuse large B‐cell lymphoma
por: Tian, Tian, et al.
Publicado: (2020)

Prediction of survival of diffuse large B‐cell lymphoma patients via the expression of three inflammatory genes
por: Zhao, Shuangtao, et al.
Publicado: (2016)

The average relative dose intensity of R‐CHOP is an independent factor determining favorable overall survival in diffuse large B‐cell lymphoma patients
por: Długosz‐Danecka, Monika, et al.
Publicado: (2019)

Complications and outcomes in diffuse large B‐cell lymphoma with gastric lesions treated with R‐CHOP
por: Kadota, Tomohiro, et al.
Publicado: (2019)

Differential expression of miRNAs as biomarkers for predicting the outcomes of diffuse large B-cell lymphoma patients
por: Hu, Maogui, et al.
Publicado: (2021)

Coexpression of CD5 and CD43 predicts worse prognosis in diffuse large B‐cell lymphoma
por: Ma, Xiao‐bo, et al.
Publicado: (2018)

Identification of an individualized RNA binding protein‐based prognostic signature for diffuse large B‐cell lymphoma
por: Xie, Yongzhi, et al.
Publicado: (2021)

Bone marrow biopsy superiority over PET/CT in predicting progression‐free survival in a homogeneously‐treated cohort of diffuse large B‐cell lymphoma
por: Chen‐Liang, Tzu‐Hua, et al.
Publicado: (2017)

A better prediction of progression‐free survival in diffuse large B‐cell lymphoma by a prognostic model consisting of baseline TLG and %ΔSUV(max)
por: Zhang, Yi‐Yang, et al.
Publicado: (2019)

Machine learning‐based classification of diffuse large B‐cell lymphoma patients by eight gene expression profiles
por: Zhao, Shuangtao, et al.
Publicado: (2016)

Comparison of PD‐L1 detection assays and corresponding significance in evaluation of diffuse large B‐cell lymphoma
por: Huang, Sixia, et al.
Publicado: (2019)

OSdlbcl: An online consensus survival analysis web server based on gene expression profiles of diffuse large B‐cell lymphoma
por: Dong, Huan, et al.
Publicado: (2020)

Surgery shows survival benefit in patients with primary intestinal diffuse large B‐cell lymphoma: A population‐based study
por: Wang, Moran, et al.
Publicado: (2021)

Outcomes after (90)Yttrium-ibritumomab tiuxetan-BEAM in diffuse large B-cell lymphoma: a meta-analysis
por: Auger-Quittet, Sophie, et al.
Publicado: (2014)

Central nervous system relapse in patients over 80 years with diffuse large B‐cell lymphoma: an analysis of two LYSA studies
por: Cabannes‐Hamy, Aurélie, et al.
Publicado: (2018)

Role of radiation therapy in primary breast diffuse large B‐cell lymphoma in the Rituximab era: a SEER database analysis
por: Liu, Pan‐pan, et al.
Publicado: (2018)

MicroRNA-142 is mutated in about 20% of diffuse large B-cell lymphoma
por: Kwanhian, Wiyada, et al.
Publicado: (2012)

Diffuse Large B-Cell Lymphoma in the Era of Precision Oncology: How Imaging Is Helpful
por: Shah, Hina J., et al.
Publicado: (2017)

The prognostic significance of monoclonal immunoglobulin gene rearrangement in conjunction with histologic B‐cell aggregates in the bone marrow of patients with diffuse large B‐cell lymphoma
por: Cho, Yoon Ah, et al.
Publicado: (2016)

Simplicity at the cost of predictive accuracy in diffuse large B‐cell lymphoma: a critical assessment of the R‐IPI, IPI, and NCCN‐IPI
por: Biccler, Jorne, et al.
Publicado: (2017)

Clinicopathological analysis of primary refractory diffuse large B‐cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone chemoimmunotherapy
por: Suzuki, Tomotaka, et al.
Publicado: (2021)

Evidence to guide the optimal timing for pre‐chemotherapy blood tests for early breast, colorectal cancer and diffuse large B‐cell lymphoma
por: Chambers, Pinkie, et al.
Publicado: (2021)

β-Elemene suppresses tumor growth of diffuse large B-cell lymphoma through regulating lncRNA HULC-mediated apoptotic pathway
por: Hu, Tonglin, et al.
Publicado: (2020)

Expressions of SH3BP5, LMO3, and SNAP25 in diffuse large B‐cell lymphoma cells and their association with clinical features
por: Kobayashi, Kyoko, et al.
Publicado: (2016)

PD‐1 expression on the surface of peripheral blood CD4(+) T cell and its association with the prognosis of patients with diffuse large B‐cell lymphoma
por: Zhang, Wei, et al.
Publicado: (2016)

Chromosomal abnormality variation detected by G‐banding is associated with prognosis of diffuse large B‐cell lymphoma treated by R‐CHOP‐based therapy
por: Mizuno, Yoshimi, et al.
Publicado: (2018)

Cutaneous diffuse large B‐cell lymphoma
por: Duarte Ribeiro, Filipa, et al.
Publicado: (2017)

Human Leukocyte Antigen Class I and II Alleles and Overall Survival in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
por: Lu, Yani, et al.
Publicado: (2011)

The beneficial effect of Escalated‐R‐CHOP‐21 for the treatment of diffuse large B‐cell lymphoma in elderly male patients: A propensity‐matched cohort study
por: He, Hai‐Xia, et al.
Publicado: (2021)

Clinicopathological analysis of primary intestinal diffuse large B‐cell lymphoma: Prognostic evaluation of CD5, PD‐L1, and Epstein‐Barr virus on tumor cells
por: Ishikawa, Eri, et al.
Publicado: (2018)

Phase II trial of co‐administration of CD19‐ and CD20‐targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma
por: Sang, Wei, et al.
Publicado: (2020)

High pretreatment plasma Epstein‐Barr virus (EBV) DNA level is a poor prognostic marker in HIV‐associated, EBV‐negative diffuse large B‐cell lymphoma in Malawi
por: Montgomery, Nathan D., et al.
Publicado: (2019)

Real‐world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B‐cell lymphoma
por: Iacoboni, Gloria, et al.
Publicado: (2021)

miR‐155‐regulated mTOR and Toll‐like receptor 5 in gastric diffuse large B‐cell lymphoma
por: Huang, Wei‐Ting, et al.
Publicado: (2021)

Diffuse large B‐cell lymphoma mimicking cardiac amyloidosis
por: Lau, Lawrence, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_hbq2rj99ehn8e6vgmcnoa6olus